Exonate announces collaboration to develop retinal disease treatment
Click Here to Manage Email Alerts
Exonate announced a collaboration with Janssen Pharmaceuticals to develop new eye drops to treat retinal vascular diseases.
This program may improve treatment for patients with retinal vascular diseases and quality of life of those with vision loss, the company said in a press release.
Through this collaboration, Exonate will work with Janssen scientists to develop an eye drop treatment for diseases such as wet age-related macular degeneration and diabetic macular edema using mRNA-targeted therapies, according to the release.
“We are looking forward to successfully developing a novel treatment for retinal neovascular diseases,” Catherine Beech, MB ChB OBE, Exonate CEO, said in the release.
“By applying our two companies’ expertise, this treatment has the potential to transform the lives of patients with retinal vascular diseases and those suffering from vision loss,” James List, MD, PhD, global therapeutic area head of cardiovascular and metabolism at Janssen Research & Development, told Primary Care Optometry News.
This collaboration agreement was facilitated by Johnson & Johnson Innovation, according to the release. – by Erin T. Welsh